Recent progresses and challenges in formulations of vincristine and its derivatives for hindering cancer cells

Document Type : Mini-Review

Authors

1 Department of Biology, Faculty of Science, Khorramabad, Lorestan University, Lorestan, Iran

2 Department of Biological Science, Faculty of Science, University of Kurdistan, Sanandaj, Kurdistan, Iran

10.22034/nmbj.2023.389869.1017

Abstract

Vincristine and its derivatives as an alkaloid have been applied in combination with chemotherapeutic drugs for the inhibition of several cancers involving small-cell lung cancer, lymphocytic leukemia, Hodgkin's disease, acute myeloid leukemia, and neuroblastoma. The main advantage of using this bioactive compound is its severe side effects specifically dose-dependent peripheral neuropathy (brain dysfunction, cranial nerve palsies, paresthesia, and gait disorder). Combination therapy using other anticancer drugs or anticancer natural compounds can synergize anticancer effects. Moreover, drug delivery systems in the nanoscale may be suitable options to decrease side effects by reducing an effective dose of vincristine. Therefore, this mini-review has tried to cover recent progress and limitations of vincristine formulations for cancers of lung cancer, acute lymphocytic leukemia, and acute myeloid leukemia.

Graphical Abstract

Recent progresses and challenges in formulations of vincristine and its derivatives for hindering cancer cells

Keywords

Main Subjects

Rights and permissions

© 2023 by the NMB. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

Nano Micro Biosystems
Volume 2, Issue 1
March 2023
Pages 36-41

Files

History

  • Receive Date: 14 March 2023
  • Revise Date: 01 April 2023
  • Accept Date: 01 April 2023

Share

How to cite

Statistics